Member Info for MisterPositive

Stephen11
In my view this would go above 50p on full NICE recommendation this month. This touched 40p just on NICE preliminary recommendation in Feb.

FDA Pre-submission update for AIHL should come straight after that. Can come early also.

NICE consultation on Stroke tests starts in April.

I see this heading towards 80 - 100p in weeks ahead.

Funding @40p would be my ideal scenario soon after NICE approval. Once done this would shoot higher towards 80 - 100p in my judgment. GLA.

Traders can always trade it on the uptrend which is where i see this going forward with Multiple price moving catalysts ahead. Dont know why they have to bash a share just to get a lower entry. You can buy on the up and set higher exit price also.

Ongoing sales and distribution deals for AIHL market launch should keep GDR in strong uptrend.

By that time Stroke tests (currently with NICE) should also come in play. FDA updates etc etc.
NICE commands high respect globally so other Healthcare bodies globally would pay attention to NICE endorsement for AIHL tests for starters.

AIHL tests market will be big for Genedrive Plc.
stroke diagnostic tests market is already established and expected to grow to $65.45 billion by 2030.

Stroke tests matket is more established and currently around $39-$40 billion globally.

AIHL tests market is new as there is NO comparable test available on market. So Genedrive will take this forward and set their own market globally starting with NHS deals with lot more to follow in coming months.

Both AIHL and stroke tests are company makers.
At only 22m MCap this is a steal. Even a sniff from Big Pharma would rocket this to £2 in no time. But first things first...lets roll out AIHL tests which alone in coming years would be Multi-billion market globally.

Never been so relaxed before. Genedrive looks a potential FTSE 250 candidate in my view. GLA

Yeah. Pretty obvious. Everyone wants a lower entry price to get back in before fireworks start. Just few weeks to go. Has someone ordered the rocket fuel yet...LoL

MyIPA
Excellent post @ 8:29 am

Highly recommended.

I have said same we have a top quality AIHL test with results within an hour. No competition. Raise around 30p or higher after March very much on.

This placing would be mainly for product launch and marketing/ distribution costs and some admin costs. Not some lifestyle running costs.

If a placing is needed to launch "in demand" product with no current market competition and grows company Market Cap towards £250-400m moving forward with both AIHL and Stroke tests, then buying at 30p would seem like a massive bargain price.

Another point is we have developed unique cutting edge AIHL test with NO competition with super fast results turnaround time.

We not selling some ASDA smart price baked beans...LoL.

Genedrive should command a premium with a product highly in demand and new market all exclusively available at GDR only.

Guy
I am not against funding but my counter argument is we got 4 months till end of June. With news due on both fronts FDA Pre-submission and NICE full recommendation report within 4 weeks we can raise at higher price.

With just over 92m total shares here, GDR will rocket upwards like anything.

Do NICE and FDA have any information sharing agreement if anyone knows please share. I mean NICE being highly respected institute in Healthcare space would command lot of respect at FDA.

Brighty1
Good post. Agree both Upfront payment from licencing deal or Venture Capital investment are very real options. If either of news drops this will be over 30p in 10 minutes.

We got funds till June 2023. Some posters scaremongering for their own selfish reason to load up on the cheap here. Why would they be posting here otherwise. Pretty obvious really.

Folks.
Please focus on your investment NOT people.
No body cares...who said what....end of.

Try to engage in more positive discussion around future growth projections in both UK and USA for starters and then stroke test.

BigAl started a good discussion but someone we keep devuating and drifting on personal vendetta.

Stephen11
Good post. Have seen placings also at a premium across many companies.

Genedrive Plc have a product that is "first to market" with a growing demand for AIHL as it benefits both supplier (GDR) and customers immensely.

Some good posts from BigAl on revenue projections for Genedrive and cost savings for NHS. These numbers will grow even more from wider roll out across the U.K. We not even looked at U.S. revenue projections from AIHL roll out.

Roger been banging on about big discounted placing for past 2 months ??? for selfish reasons obviously to load up on the cheap. Then we had another m0r0n "bankrupt" with his deramping and scaremongering on Friday...amongst others.

Market will re-rate this on future outlook not past history. Genedrive is now very well positioned from AIHL roll out in both UK and USA which brings Genedrive lot more media coverage. Successful AIHL roll out will then feed onto our Stroke tests product (also with NICE currently) which is a Huge market as we know and expected to hit over $65 billion by 2030.

Scumbagggg shorters trying to support their Short positions!!!!

Deramping and scaremongering of highest order today

Irrespective of bear or Bull market, with the right product and growing demand, you can make huge gains.

GDR is perfectly poised to finally cash in with 2 of their key products AIHL and stroke tests with huge market potential globally.

Its a Stock pickers market. GDR is well positioned.

Genedrive over the years through cutting edge scientific innovation have repeatedly produced tests with fastest results turnaround times.

Genedrive has a strong edge in a niche market with AIHL tests. No competition.

Even stroke marker test (currently also with NICE) produces results within an Hour.

For AIHL, Genedrive will set the market with ever growing demand for quick results from the Pharma Healthcare industry. Margins can be very lucrative when you are the only supplier. Just get your Sales team and Distributors active.

Stroke tests will be next.

Getting passed NICE excellence standards is a big achievement for GDR with a unique test all to GDR themselves.

Take on board also points about slight initial discount to get orders in. Tricky one that.

With a unique test "first to market" and growing demand with benefits for all parties; patients, NHS and Big Pharma who can package up AIHL tests along other services to their customers worldwide as this is global issue.

We need 10 year projections on AIHL sales:
Sale price
cost per kit
Units sold
NPV10 values etc.

Keep in mind unlike stroke test diagnostic market, there is no AIHL tests market currently. GDR is the first company and will set the market instead of grabbing market share from other companies for AIHL tests. So we do need to get initial pricing right.

Nissan
Excellent work on forthcoming events calendar.

Genedrive will gain more coverage & recognition.

Longtermholder
Well said. Too much short termism. Some folks just focused on short term exit strategy. Thats fine their money their decision. But in my personal view this is the time to build as this company takes both AIHL and stroke tests to market and grows substantially.

With GDR now fast tracking both AIHL and Stroke tests up the chain we can expect Explosive Upside here. AIHL tests having already received preliminary recommendation from NICE.

National institute of Healthcare & Clinical Excellence (NICE). It carries lot of respect, so a recommendation from NICE holds lot of weight.

FDA update is next which can come any day.

Back on 16 Aug 2013 closing price was £5.67

We had less shares in issue then. Even today we got only 92.5m total shares.

With AIHL almost ready to be launched in UK and first to market with NO other comparable test on market we can write our own cheque. GLA

Guy
You cheapskate...LoL

Should have been A* minimum

Even now GDR only has 92.5m total shares in issue which is feckk all.

With AIHL launch in UK soon we should have money coming in from NHS multi-year contracts.
Then add on all those Private Clinics / hospitals.

AIHL revenue stream from USA would be many multiples of UK market soon after FDA approval after the Pre-submission.

Not even looked at our Stroke tests targeting $65.45 billion Global market by 2030. Currently global narket is around $39b - $40 billion.

So HUGE UPSIDE with multiple price moving catalysts ahead.

Company can raise £10m from just issuing 20m shares @ 50p in months ahead and still total shares will be 112m only.